Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilities

Abstract

Small-cell lung cancer (SCLC) has long been characterized by its aggressive clinical course and a deceptive initial sensitivity to chemotherapy that almost invariably yields to recalcitrant disease. Recent genomic and transcriptomic profiling has dismantled the historical view of SCLC as a monolithic entity, revealing a complex landscape of inter- and intra-tumoral heterogeneity defined by the differential expression of key transcription factors—ASCL1, NEUROD1, POU2F3, and YAP1. Central to this heterogeneity is the phenomenon of lineage infidelity, a form of cellular plasticity where SCLC cells transit between molecularly distinct states to evade physiological and therapeutic pressures. In this review, we decode the epigenetic and transcriptional networks that govern these subtype transitions, highlighting how the loss of canonical lineage markers drives the emergence of variant phenotypes with altered metabolic and tumor profiles. We argue that this plasticity is not merely a byproduct of tumor evolution but a fundamental engine of chemoresistance. Crucially, we identify the acquired therapeutic vulnerabilities inherent to each state, proposing a transition from broad-spectrum cytotoxic regimens to a trajectory-based precision medicine framework. By targeting the gatekeepers of lineage identity and exploiting the transient weakness of emerging subtypes, we outline a roadmap for overcoming the historical stalemate in SCLC treatment and achieving sustained clinical responses.

Keywords

Small-Cell Lung Cancer / Lineage Infidelity / Phenotypic Plasticity / Epigenetic Reprogramming

References

[1] Misona S, Mizuna K, Suetsugu T, et al.. Molecular signature of small cell lung cancer after treatment failure: the MCM complex as therapeutic target. Cancers, 2021, 13: 1187

[2] Von Itzstein MS, Drapkin BJ, Minna JD. Lineage switching: how lung cancer cells change identity. Elife, 2021, 10: e71610

[3] Li X, Gardner EE, Molina-Pinelo et al. Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Res. 2025; 35(11): 803–823 https://doi.org/10.1038/s41422-025-01180-x

[4] Dai X, Hao Y, Hong J, et al.. Molecular mechanisms and clinical insights in transformed small cell lung cancer: a narrative review. Transl Lung Cancer Res, 2025, 31: 3233-3248

[5] Gay CM, Stewart CA, Park EM, et al.. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39(3): 360e7

[6] Papavassiliou KA, Sofianidi AA, Gogou VA, et al.. P53 and RB aberrations in small cell lung cancer: from molecular mechanism to therapeutic modulation. Intl J Mol Sci, 2023, 24(9): 1-8

[7] Kim, Kim S, Park SY, et al. Molecular subtypes and tumor microenvironment characteristics of small cell lung cancer associated with platinum-resistance. Cancers (Basel). 2023;15(14):3568 https://doi.org/10.3390/cancers15143568

[8] Zhang J, Zeng X, Guo Q, et al.. small cell lung cancer: emerging subtypes, signalling pathways, and therapeutic vulnerabilities. Exp Hematol Oncol, 2024, 13(1): 78

[9] Redin E, Sridhar H, Zhang YA, et al.. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol, 2024, 17(1): 58

[10] Lam LT, Lin X, Faivre EJ, et al.. Vulnrerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors. Mol Cancer Ther, 2017, 16(8): 1511-1520

[11] Shiba-Ishii A, Takemura N, Kawai H, et al.. Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: current knowledge of genetic changes and molecular mechanisms. Cancer Sci, 2024, 115(7): 2138-2146

[12] Takahashi N, Pongor L, Agrawal SP. Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor. Genome Med, 2025, 17(1): Article ID: 15

[13] Solta A, Ernhofer B, Boettiger K, et al.. Small cells-big issues: biological implications and preclinical advancements in small cell lung cancer. Mol Cancer, 2024, 23(1): 41

[14] Jing M, He X, Cai CZ, et al.. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer. Biochem Biophys Res Commun, 2023, 681: 218-224

[15] Duplaquet L, Li Y, Booker MA, et al.. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer. Nat Cell Biol, 2023, 25(9): 1346-1358

[16] Denninghoff V, Russo A, de Miguel-Perez D, et al.. Small cell lung cancer: state of the art of the molecular and genetic landscape and novel perspective. Cancers, 2021, 13(7): 1723

[17] Zhang C, Wu BZ, Thu KL. Targeting kinesins for therapeutic exploitation of lung chromosomal instability in lung cancer. Cancers, 2025, 17(4): 685

[18] Wang X, Zeng X, Li D, et al.. PARP inhibitors in small cell lung cancer: the underlying mechanisms and clinical implications. Biomed Pharmacother, 2022, 153: 113458

[19] Yu M, Chen Y, Li X, et al.. YAP1 invasion and migration by promoting Slug transcription via the transcription co-factor TEAD. Cell Death Dis, 2018, 9(5): 464

[20] Stewart CA, Gay CM, Xi Y, et al.. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer, 2020, 1: 423-436

[21] George J, Maas L, Abedpour N, et al.. Evolutionary trajectories of small cell lung cancer under therapy. Nature, 2024, 627(8005): 880-889

[22] Acar A, Nichol D, Fernandez-Mateos J, et al.. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nat Commun, 2020, 11: 1923

[23] Soragni A, Knudsen ES, O’Connor TN, et al.. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer, 2025, 25(8): 613-633

[24] Li Q, Wang R, Yang Z, et al.. Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq. Genome Med, 2022, 14(1): 87

[25] Heeke S, Gay CM, Estecio MR, et al.. Tumor-and circulating-free DAN methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell, 2024, 42(2): 225-237.e5

[26] He Y, Xiaorong T, Yang F. Exploring resistance to initial chemotherapy in small cell lung cancer. Medicine. 2025; 104 (e41953):12 https://doi.org/10.10097/MD.00000000041953

RIGHTS & PERMISSIONS

The Author(s)